Fortrea Holdings (FTRE) Other Operating Expenses (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Other Operating Expenses came in at $561.3 million in Q2 2026, down 38.71% YoY from $915.8 million in Q2 2025, and up 4.06% on a QoQ basis from $539.4 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Other Operating Expenses (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Other Operating Expenses data on file, last reported at $561.3 million in Q2 2026.
- Quarterly Other Operating Expenses fell 38.71% year-over-year to $561.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.3 billion (down 27.24% YoY) and the FY2025 annual result came in at $3.1 billion, up 36.65% from the prior year.
- Other Operating Expenses climbed to $561.3 million in Q2 2026, from $539.4 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $1.0 billion in Q1 2025 to a low of $286.0 million in Q4 2022.
- A 5-year average of $612.8 million and a median of $585.1 million in 2023 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2023 — Other Operating Expenses jumped 109.58% — and 2026, when it slumped 48.61%.
- Tracing FTRE's Other Operating Expenses over 5 years: stood at $286.0 million in 2022, then soared by 109.58% to $599.4 million in 2023, then increased by 0.85% to $604.5 million in 2024, then slipped by 5.53% to $571.1 million in 2025, then retreated by 1.72% to $561.3 million in 2026.
- The last three Other Operating Expenses figures came in at $561.3 million (Q2 2026), $539.4 million (Q1 2026), and $571.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.71 Bn | 1.54 Bn | 139.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 558.60 Mn |
| Mar 31, 2026 | 532.70 Mn |
| Dec 31, 2025 | 548.70 Mn |
| Sep 30, 2025 | 598.20 Mn |
| Jun 30, 2025 | 905.50 Mn |
| Mar 31, 2025 | 1.04 Bn |
| Dec 31, 2024 | 576.90 Mn |
| Sep 30, 2024 | 547.80 Mn |
| Jun 30, 2024 | 546.70 Mn |
| Mar 31, 2024 | 576.10 Mn |
| Dec 31, 2023 | 600.10 Mn |
| Sep 30, 2023 | 586.60 Mn |
| Jun 30, 2023 | 592.10 Mn |
| Mar 31, 2023 | 562.40 Mn |
| Dec 31, 2022 | 290.60 Mn |
| Sep 30, 2022 | 617.50 Mn |
| Jun 30, 2022 | 637.70 Mn |